Statiner, som er substrater af CYP3A, forventes derfor ikke at have en virkning på prasugrels farmakokinetik eller dets hæmning af blodpladeaggregering.
Therefore, statins that are substrates of CYP3A are not anticipated to have an effect on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.